Last reviewed · How we verify
NCT03444753
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Phase 1 trial testing BMS-986299 in Advanced Cancer in 82 participants. Terminated before completion.
14 February 2022
Quick facts
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 82 |
| Start date | 5 April 2018 |
| Primary completion | 14 February 2022 |
| Estimated completion | 14 February 2022 |
| Sites | 9 locations across United States |
Drugs / interventions tested
- BMS-986299 — full drug profile →
- Nivolumab (nivolumab) — full drug profile →
- Ipilimumab — full drug profile →
Conditions studied
- Advanced Cancer — all drugs for Advanced Cancer →
Sponsor
Bristol-Myers Squibb — full company profile →
Who can join
18 and older, any sex, with Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether BMS-986299 both by itself and in combination with Nivolumab and Ipilimumab is safe and tolerable in the treatment of advanced solid tumors. In addition, the ability of study drugs to stimulate an immune response against cancer will be investigated.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic modulation of inflammasome pathways.
Chauhan D, Vande Walle L, Lamkanfi M. · · 2020 · cited 163× · PMID 32770571 · DOI 10.1111/imr.12908 -
Harnessing innate immune pathways for therapeutic advancement in cancer.
Hu A, Sun L, Lin H, Liao Y, et al · · 2024 · cited 150× · PMID 38523155 · DOI 10.1038/s41392-024-01765-9 -
NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer.
Faria SS, Costantini S, de Lima VCC, de Andrade VP, et al · · 2021 · cited 144× · PMID 33840390 · DOI 10.1186/s12929-021-00724-8 -
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting.
Broderick L, Hoffman HM. · · 2022 · cited 112× · PMID 35729334 · DOI 10.1038/s41584-022-00797-1 -
Targeting Innate Immunity in Cancer Therapy.
Rameshbabu S, Labadie BW, Argulian A, Patnaik A. · · 2021 · cited 90× · PMID 33572196 · DOI 10.3390/vaccines9020138 -
NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders.
Ramachandran R, Manan A, Kim J, Choi S. · · 2024 · cited 67× · PMID 38945951 · DOI 10.1038/s12276-024-01261-8 -
Involvement of inflammasomes in tumor microenvironment and tumor therapies.
Zhang Z, Li X, Wang Y, Wei Y, et al · · 2023 · cited 55× · PMID 36932407 · DOI 10.1186/s13045-023-01407-7 -
The discovery of NLRP3 and its function in cryopyrin-associated periodic syndromes and innate immunity.
Putnam CD, Broderick L, Hoffman HM. · · 2024 · cited 27× · PMID 38146057 · DOI 10.1111/imr.13292
Verify or expand the search:
- PubMed search for NCT03444753
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Cancer
Currently open trials in the same condition.
- NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
- NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
- NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
- NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
- NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting
Other Bristol-Myers Squibb trials
Trials by the same sponsor.
- NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
- NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
- NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
- NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03444753 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
- Last refreshed: 23 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03444753.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing